logo-loader
viewCircassia Pharmaceuticals PLC

Price Monitoring Extension

RNS Number : 5225C
Circassia Pharmaceuticals Plc
17 June 2019
 

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
PMEBUGDLUXBBGCR

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.15

Market: LSE
Market Cap: £64.34 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19